Savara

+$0.01 (+0.81%) As of 12:58 PM UTC pre-market

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis.

CEO
Matthew Pauls
Employees
27
Headquarters
Austin, Texas
Founded
1995

SVRA Key Statistics

Market Cap
141.17M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
269.52K
High Today
$1.30
Low Today
$1.23
Open Price
$1.30
Volume
397.37K
52 Week High
$3.58
52 Week Low
$0.9952

SVRA Earnings

-$0.27
-$0.18
-$0.09
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Nov 4
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure